Literature DB >> 12900303

The relationship of clozapine and haloperidol treatment response to prefrontal, hippocampal, and caudate brain volumes.

Celso Arango1, Alan Breier, Robert McMahon, William T Carpenter, Robert W Buchanan.   

Abstract

OBJECTIVE: The study was designed to assess the predictive relationship between brain structure volume and positive and negative symptom response to clozapine and haloperidol.
METHOD: Partially responsive outpatients with schizophrenia who participated in a 10-week, parallel-group, double-blind comparison of clozapine and haloperidol and who had an available magnetic resonance imaging scan were included in the current study. Prefrontal gray and white matter, hippocampal, and caudate volumes were manually measured. The Scale for the Assessment of Negative Symptoms (SANS) and the Brief Psychiatric Rating Scale (BPRS) were used to assess symptom changes. The Simpson-Angus Rating Scale was used to assess extrapyramidal symptoms.
RESULTS: Twenty-two patients randomly assigned to clozapine and 23 patients assigned to haloperidol met study entry criteria. There were significant interactions between treatment and right prefrontal gray matter volume for BPRS total score and SANS total score. There were no significant treatment-by-brain structure interactions for BPRS positive symptom items. Right prefrontal gray matter volume was also related to differential treatment effects for the BPRS subscales of anxiety/depression and hostility and the Simpson-Angus Rating Scale akathisia item.
CONCLUSIONS: These results suggest that there is a differential interaction among clozapine and haloperidol, brain structure, and treatment response. Partially responsive patients with larger brain volumes may be more likely to experience the benefits of clozapine treatment, but they may be more vulnerable to side effects and experience a subsequent worsening of their symptoms when treated with haloperidol.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12900303     DOI: 10.1176/appi.ajp.160.8.1421

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  32 in total

1.  Evidence for white matter abnormalities in schizophrenia.

Authors:  Marek Kubicki; Robert W McCarley; Martha E Shenton
Journal:  Curr Opin Psychiatry       Date:  2005-03       Impact factor: 4.741

2.  Survey of protocols for the manual segmentation of the hippocampus: preparatory steps towards a joint EADC-ADNI harmonized protocol.

Authors:  Marina Boccardi; Rossana Ganzola; Martina Bocchetta; Michela Pievani; Alberto Redolfi; George Bartzokis; Richard Camicioli; John G Csernansky; Mony J de Leon; Leyla deToledo-Morrell; Ronald J Killiany; Stéphane Lehéricy; Johannes Pantel; Jens C Pruessner; H Soininen; Craig Watson; Simon Duchesne; Clifford R Jack; Giovanni B Frisoni
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

3.  Magnetic resonance imaging predictors of treatment response in first-episode schizophrenia.

Authors:  Philip R Szeszko; Katherine L Narr; Owen R Phillips; Joanne McCormack; Serge Sevy; Handan Gunduz-Bruce; John M Kane; Robert M Bilder; Delbert G Robinson
Journal:  Schizophr Bull       Date:  2010-11-17       Impact factor: 9.306

Review 4.  [One decade of functional imaging in schizophrenia research. From visualisation of basic information processing steps to molecular-genetic oriented imaging].

Authors:  H Tost; A Meyer-Lindenberg; M Ruf; T Demirakça; O Grimm; F A Henn; G Ende
Journal:  Radiologe       Date:  2005-02       Impact factor: 0.635

Review 5.  Predictors and markers of clozapine response.

Authors:  Carmen Chung; Gary Remington
Journal:  Psychopharmacology (Berl)       Date:  2005-02-17       Impact factor: 4.530

Review 6.  Neuroimaging markers of antipsychotic treatment response in schizophrenia: An overview of magnetic resonance imaging studies.

Authors:  Goda Tarcijonas; Deepak K Sarpal
Journal:  Neurobiol Dis       Date:  2018-06-25       Impact factor: 5.996

7.  Fine-tuning of awake prefrontal cortex neurons by clozapine: comparison with haloperidol and N-desmethylclozapine.

Authors:  Houman Homayoun; Bita Moghaddam
Journal:  Biol Psychiatry       Date:  2006-10-13       Impact factor: 13.382

8.  Quantitative MRI measures of orbitofrontal cortex in patients with chronic schizophrenia or schizoaffective disorder.

Authors:  Matthew J Hoptman; Jan Volavka; Elisabeth M Weiss; Pál Czobor; Philip R Szeszko; Guido Gerig; Miranda Chakos; Joseph Blocher; Leslie L Citrome; Jean-Pierre Lindenmayer; Brian Sheitman; Jeffrey A Lieberman; Robert M Bilder
Journal:  Psychiatry Res       Date:  2005-10-25       Impact factor: 3.222

Review 9.  Neuroimaging findings in treatment-resistant schizophrenia: A systematic review: Lack of neuroimaging correlates of treatment-resistant schizophrenia.

Authors:  Shinichiro Nakajima; Hiroyoshi Takeuchi; Eric Plitman; Gagan Fervaha; Philip Gerretsen; Fernando Caravaggio; Jun Ku Chung; Yusuke Iwata; Gary Remington; Ariel Graff-Guerrero
Journal:  Schizophr Res       Date:  2015-02-13       Impact factor: 4.939

Review 10.  Basal ganglia pathology in schizophrenia: dopamine connections and anomalies.

Authors:  Emma Perez-Costas; Miguel Melendez-Ferro; Rosalinda C Roberts
Journal:  J Neurochem       Date:  2010-01-20       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.